Bessor Pharma


Bessor Pharma is utilizing an innovative technology and business model for new drug development and value creation, with a focus on translating opportunities from university laboratories into proof-of-concept or clinical-ready packages for the pharma/biotech industry. The Company, which has unique skills, connectivity, and capital markets sophistication, is forging an ecosystem of academic and industry partners as key stakeholders facilitating translational R&D. Bessor is differentiated by its: aligned team with an unparalleled track record in drug development; operational progress; and unique collaborative partnerships fueling an innovative pipeline of highly needed drugs.

We have built a highly experienced and engaged leadership team and advisors that are committed to the translational development of our projects. Collectively, our team and advisors have been instrumental in the development of nearly 20 marketed drugs, including: Tykerb® (lapatinib), Gemzar® (gemcitabine), Coreg™ (carvedilol), and Corlopam® (fenoldopam).

Download a PDF of Bessor’s corporate profile


Barry A. Berkowitz, PhD, Chairman of the Board of Directors and CEO

Read Bio

Barry has founded, built and led highly successful drug discovery and development organizations in start-up and large pharmaceutical environments for nearly 40 years. He has built value around the companies he has led through numerous strategic transactions, including alliances with major pharma companies, such as Eli Lilly, Pfizer, Wyeth and Bristol Myers Squibb as well as M&A. Companies he has co-founded and or led as CEO include: Myco/Chemgenics (acquired by Millennium Pharmaceuticals); New Chemical Entities (acquired by Albany Molecular); and Fibrogen. Earlier in his career, he held senior research positions at Smith, Kline & French, and the Roche Institute of Molecular Biology. Barry holds a BS degree in Pharmacy from Northeastern University and a PhD in Pharmacology from the University of California.

Allan M. Cohen, Esq, CPA, Vice President Licensing and General Counsel

Read Bio

Allan leads Bessor’s licensing, business, and legal activities. He has over 20 years of experience as a corporate lawyer, accountant, and management team member in the life sciences, technology, and financial services spaces. Previously, he was part of the leadership team and headed the legal function at Auven Therapeutics f/k/a Celtic Therapeutics and Celtic Pharma, hybrid private equity and virtual drug development firms. Prior to joining Celtic, he worked in the general counsel’s offices at Goldman Sachs and American Express, served as general counsel of a publicly-traded technology incubator, and was a corporate attorney at McDermott, Will & Emery. Allan earned a J.D. from the University of Virginia School of Law and a B.S. in Accounting from Penn State. Prior to law school he worked at Arthur Andersen.

Wallace Dairman, PhD, Vice President of Toxicology and Drug Development

Read Bio

Wally has had a more than 40 year-career in toxicology and drug development at Hoffman-La Roche and as a consultant. During a 20-year career at Roche, he was responsible for the design and execution of many GLP toxicity and toxicokinetic studies supporting IND, NDA, and PLA applications (e.g. midazolam, interferon, carbachol). Previously, he conducted basic research in molecular pharmacology at the Roche Institute of Molecular Biology and held research positions at Lederle. Wally hold a BS degree in Pharmacy from Rutgers and a PhD in Biochemical Pharmacology from Tufts University.

Martin Hynes, PhD, Vice President Project Management and Quality Assurance

Read Bio

Marty joined Bessor following a more than 35-year career at Eli Lilly and Company, with a particular focus on the areas of project management and quality assurance supporting global drug development efforts. He has led multiple development teams for drugs including human growth hormone (Humatrope®), atomoxetine (Strattera®) and pergolide (Permax®). He holds a BA degree in Psychology from Providence College, and MS and PhD degrees in Pharmacology and Toxicology from the University of Rhode Island.

Satish Menon PhD, VP Biotechnology R&D

Read Bio

Satish has more than 25 years of industrial experience in biological (proteins, peptides, vaccines) drug substance and analytical development, and manufacturing, at multiple companies including the DNAX Research Institute, Allergan, and Schering-Plough. He has participated in the development of many drugs, including three that are marketed (alpha interferon, GM-CSF, and clostridium, botulinium neurotoxin). He holds BS and MS degrees in Microbiology from Pune University and G.B. Pant University (both in India), and a PhD in Biochemistry from the Indian Institute of Science (India).

Robert Morgan, CPA, CFO

Read Bio

Robert has more than 15 years of senior management and leadership experience in entrepreneurial technology companies. He has founded or played a role in launching more than a dozen venture-backed companies. He is a former Senior Vice-President of Flagship Ventures. Earlier in his career, Robert was the founder and for six years was a principal of a business consultancy specializing in providing strategic, operational and finance related services to entrepreneurial companies. In addition, he spent the first seven years of his career in public accounting and served as a Manager in the Small Business Group of Price Waterhouse, Boston. Robert is a Certified Public Accountant and received his B.S. in Accounting from the University of Massachusetts, Lowell.

Eliot Ohlstein, PhD, VP Pharmacologic R&D

Read Bio

Eliot has held senior research, and research leadership positions drug discovery and development in the pharmaceutical industry for more than 35 years. Previously, he served at Glaxo SmithKline, most recently as a Senior Vice President Drug Discovery and Development, where he was involved in cardiovascular, metabolic, renal and oncology therapeutics, with both small, large and peptide molecules. In addition to Bessor, he serves as Head of Research & Development and Chief Scientific Officer at Velicept Pharmaceuticals. He is an author on more than 275 publications on drug discovery and development for new therapeutic targets.
Eliot holds a BS in Pharmacy from the Massachusetts College of Pharmacy and a PhD in Pharmacology from the Tulane University School of Medicine.

Mark Roffman, PhD, Vice President of Drug Development and Regulatory Affairs

Read Bio

Mark has more than 30-years of experience in drug development and project management, and with both large and small pharmaceutical companies. He has led numerous project teams, overseeing drug development. Prior to Bessor, he served as Vice President for Drug Development at several companies, including XTL Biopharmaceuticals and Relox Medical, and served in a number of roles at Smith, Kline & French and Ciba-Geigy. Mark holds an AB degree in Biology from Boston University and MS and PhD degrees in Pharmacology from the University of Rhode Island.